U.S. Metals and Mining Stock News

NasdaqGS:HLIT
NasdaqGS:HLITCommunications

Harmonic (HLIT) Margin Compression To 0.3% Tests Bullish Earnings Growth Narrative

Harmonic (HLIT) has wrapped up FY 2025 with fourth quarter revenue of US$98.2 million and basic EPS of roughly US$0.00, while trailing twelve month EPS sits at US$0.01 on revenue of US$360.5 million. Over recent periods the company has seen quarterly revenue move from US$195.8 million in Q3 2024 to US$133.1 million in Q1 2025, then to US$138.0 million in Q2, US$142.4 million in Q3 and US$98.2 million in Q4, with EPS shifting from US$0.19 to US$0.05, US$0.03, US$0.02 and close to flat over the...
NasdaqGS:ECPG
NasdaqGS:ECPGConsumer Finance

Encore Capital Group (ECPG) Earnings Rebound Tests Bearish Profitability Narratives

Encore Capital Group (ECPG) just closed FY 2025 with Q4 revenue of US$473.6 million and basic EPS of US$3.43, backed by net income of US$76.7 million for the quarter. The company has seen quarterly revenue move from US$265.6 million in Q4 2024 and US$367.1 million in Q3 2024 to US$392.8 million, US$442.1 million, US$460.4 million and now US$473.6 million across the four quarters of 2025, while EPS shifted from a loss of US$9.42 in Q4 2024 to positive prints of US$1.96, US$2.50, US$3.22 and...
NYSE:TEL
NYSE:TELElectronic

The Bull Case For TE Connectivity (TEL) Could Change Following Rising Demand For Mini Board‑to‑Board Connectors

Recent commentary highlights that expansion in industrial automation, robotics, and advanced automotive electronics is boosting demand for compact, reliable board‑to‑board connectors, particularly in the 1 mm to 2 mm segment. This trend plays directly into TE Connectivity’s core strengths as a major supplier of miniaturized connectivity solutions for electric vehicles, autonomous systems, and interconnected industrial equipment. We’ll now examine how rising demand for compact...
NYSE:ACHR
NYSE:ACHRAerospace & Defense

Does Archer Aviation (ACHR) Justify Its Current Price After Recent eVTOL Milestones?

If you are wondering whether Archer Aviation's current share price lines up with its long term potential, this article will walk through what the numbers are actually saying about value. The stock last closed at US$7.38, with a 2.1% return over the past 7 days, an 8.8% decline over 30 days, a 9.2% decline year to date, a 6.8% decline over 1 year, a very large 3 year return, and a 31.5% decline over 5 years, which together may leave you questioning how the recent price levels square with the...
NasdaqGS:BELF.A
NasdaqGS:BELF.AElectronic

Is It Too Late To Consider Bel Fuse (BELFA) After Its 155% One Year Rally?

If you are wondering whether Bel Fuse's recent share price puts it on your watchlist or on your too expensive list, looking closely at its current valuation is a good next step. The stock closed at US$214.00, with returns of 11.3% over the past 30 days, 40.0% year to date and 155.0% over the last year. The 3 year and 5 year returns are very large at roughly 5x and more than 10x respectively, alongside a small 0.3% decline over the last week. Recent coverage of Bel Fuse has focused on its...
NYSE:GNK
NYSE:GNKShipping

Will Strong Q4 Results and New Dividend Payout Change Genco Shipping & Trading's (GNK) Narrative?

Genco Shipping & Trading Limited has reported its fourth-quarter 2025 results, with revenue rising to US$109.92 million and net income to US$15.41 million year over year, while also declaring a US$0.50 per-share cash dividend payable in March 2026. Despite posting a small full-year 2025 net loss after a profitable prior year, the company highlighted strong Capesize freight conditions and proactive fleet management as key drivers of its best quarterly EBITDA and vessel earnings of the...
NasdaqGM:TTD
NasdaqGM:TTDMedia

Does Trade Desk’s Strong 2025 Results And Softer Q1 2026 Outlook Change The Bull Case For TTD?

In the fourth quarter and full year 2025, The Trade Desk reported higher revenue and net income year on year, while also completing a US$2.27 billion share repurchase program and authorizing a further US$350 million for future buybacks. Despite these solid results and ongoing product expansion, including the Ventura Ecosystem in connected TV and new retail data partnerships, management’s softer-than-expected first quarter 2026 revenue outlook highlighted pressures in key advertiser...
NYSE:IOT
NYSE:IOTSoftware

Assessing Samsara (IOT) Valuation After New AI-Powered Asset Tag Launch And Expanded Tracking Network

Samsara (IOT) just rolled out its latest Asset Tag and new Asset Tag XS, integrating them into an expanded Samsara Network with Hubble’s terrestrial network to improve tracking and recovery of high-value equipment. See our latest analysis for Samsara. The new asset tracking launch comes after a volatile stretch for Samsara, with a 1 day share price return of 5.54% and 7 day share price return of 8.06% following product updates, rating changes, and broader tech sector swings. Even so, the 30...
NYSE:EL
NYSE:ELPersonal Products

Balmain Beauty Fragrance Launch Might Change The Case For Investing In Estée Lauder Companies (EL)

In February 2026, Balmain Beauty, in partnership with Estée Lauder Companies, launched Destin de Balmain, a refillable prestige fragrance available globally in multiple bottle sizes and travel format. This bold debut extends Estée Lauder’s luxury fragrance portfolio at a time when product innovation and brand collaborations are key levers for reinforcing its position in prestige beauty. We’ll now examine how this debut Balmain fragrance, alongside recent earnings strength, may influence...
NasdaqGS:GLUE
NasdaqGS:GLUEBiotechs

What Monte Rosa Therapeutics (GLUE)'s Phase 1/2 MRT-2359 Combo Data Means For Shareholders

Monte Rosa Therapeutics recently reported updated Phase 1/2 data showing that its investigational degrader MRT-2359, combined with enzalutamide, was well-tolerated and produced encouraging safety and efficacy signals in heavily pretreated metastatic castration-resistant prostate cancer patients with androgen receptor mutations, with results presented at the 2026 ASCO GU Symposium. The company also outlined plans to advance MRT-2359 into a Phase 2 study with a second-generation androgen...
NYSE:JNJ
NYSE:JNJPharmaceuticals

Jury Talc Verdict Puts Johnson And Johnson Valuation In Sharp Focus

A Philadelphia jury found Johnson & Johnson (NYSE:JNJ) liable in a talc ovarian cancer lawsuit. The verdict is the first plaintiff win in Philadelphia’s talc mass tort after years of paused litigation. Johnson & Johnson faces over 70,000 ongoing talc related lawsuits across its broader legal docket. The ruling comes as talc litigation resumes following prior bankruptcy related delays. Johnson & Johnson, a diversified healthcare company with pharmaceuticals, medical devices, and consumer...
NasdaqGS:DRS
NasdaqGS:DRSAerospace & Defense

Leonardo DRS (DRS) Valuation Check After Earnings Beat And Higher 2026 Revenue Guidance

Leonardo DRS (DRS) is back in focus after reporting quarterly and full year 2025 results, raising its 2026 revenue outlook, and pointing to continued demand across tactical radars, electric propulsion, and advanced sensing. See our latest analysis for Leonardo DRS. The latest results and guidance arrive after a strong run, with a 90 day share price return of 26.84% and a 3 year total shareholder return of about 7x, suggesting momentum has been building as investors reassess growth and risk...
NasdaqCM:LQDA
NasdaqCM:LQDAPharmaceuticals

Is Liquidia (LQDA) Pricing Reflecting Recent Volatility And Long Term Potential

If you are trying to figure out whether Liquidia's share price fairly reflects its potential, starting with a clear look at valuation can help you frame that question more confidently. The stock has been volatile recently, with a 12.2% decline over the last 7 days and a 27.5% decline over the last 30 days, even though the 1 year return is 100.5% and the 3 year return is 328.8%. These sharp swings have arrived alongside ongoing investor attention on Liquidia's position in the pharmaceuticals...
NYSE:BE
NYSE:BEElectrical

Bloom Energy Brookfield Deal Links Fuel Cells To AI Power Growth

Bloom Energy (NYSE:BE) has entered a $5b partnership with Brookfield Corporation. The agreement focuses on supplying fuel cell power solutions to AI data centers. The deal reflects growing demand for onsite, bring your own power setups in AI infrastructure. Bloom Energy builds solid oxide fuel cell systems that generate onsite electricity, targeting customers that need reliable, cleaner power with tight uptime requirements. With AI data centers scaling their computing capacity, power...
NYSE:CMG
NYSE:CMGHospitality

Chipotle Tariffs Hit Outlook As Market Weighs Valuation And Margin Risks

Chipotle Mexican Grill (NYSE:CMG) has revised its full year outlook and now expects a decline in same store sales. The change follows the sudden introduction of new global tariffs by the U.S. administration, which has increased trade policy uncertainty. Management cites potential pressure on supply chain costs and operations as key reasons for the updated guidance. For investors tracking NYSE:CMG, the update comes with the stock trading around $38.05. Shares are up 27.2% over the past 3...
NYSE:PR
NYSE:PROil and Gas

Permian Resources Q4 Records Reshape Dividend Outlook And Deal Driven Growth

Permian Resources reported record Q4 operational results, including its highest oil production and lowest drilling costs to date. The company increased its base dividend, signaling a higher level of regular cash returns to shareholders. Permian Resources also completed a series of large acquisitions, expanding its asset base and scale within its sector. For investors watching NYSE:PR, the latest update comes following a share price of $18.12 and strong multi year returns, including 34.6%...
NYSE:NIC
NYSE:NICBanks

Assessing Nicolet Bankshares (NIC) Valuation After Strong Multi‑Year Shareholder Returns

Nicolet Bankshares overview and recent stock performance Nicolet Bankshares (NIC) has drawn investor attention after recent share price moves, with the stock returning 10.2% over the past month and 25.4% in the past 3 months. Over a longer horizon, the total return stands at 31.1% year to date and 34.4% over the past year, and has more than doubled over both the past 3 years and 5 years on a total return basis. See our latest analysis for Nicolet Bankshares. Despite a small 1 day share price...
NYSE:PAYC
NYSE:PAYCProfessional Services

Does Paycom (PAYC) Centralizing Operating Power Reframe Its AI Execution And Governance Narrative?

On February 18, 2026, Paycom Software appointed long-time technology and client leader Shane Hadlock as President and Chief Client Officer, becoming its sole principal operating officer while CEO Chad Richison remains in place. At the same time, Paycom’s board updated the bylaws to broaden the CEO’s authority over the President’s role and to tighten how “Principal Competitor” is defined for governance purposes. We’ll now examine how Hadlock’s expanded operating responsibility and the revised...
NYSE:AUB
NYSE:AUBBanks

Atlantic Union Bankshares CFO Transition And What It May Mean For Valuation

Atlantic Union Bankshares (NYSE:AUB) has appointed Alexander D. Dodd as Chief Financial Officer. Dodd succeeds longtime CFO Robert M. Gorman, who served in the role for nearly 14 years. The company is planning a structured transition that includes an advisory period for Gorman. For investors watching Atlantic Union Bankshares at a share price of $39.51, a CFO transition of this kind is a meaningful leadership event. With Robert M. Gorman stepping aside after nearly 14 years and Alexander D...
NYSE:ARE
NYSE:AREHealth Care REITs

Aristotle Fund’s Exit Over Lab Oversupply Might Change The Case For Investing In Alexandria (ARE)

Alexandria Real Estate Equities, Inc. recently held a conference call and webcast on April 28, 2026, following the release of its first quarter 2026 operating and financial results after markets closed on April 27, 2026, offering management’s detailed update to shareholders and analysts. Aristotle Growth Equity Fund’s decision to exit its position in Alexandria, citing prolonged weakness and oversupply in the laboratory real estate market, brings fresh attention to how funding and regulatory...
NasdaqGS:ATEC
NasdaqGS:ATECMedical Equipment

Alphatec Holdings (ATEC) Quarterly Loss Narrowing Challenges Longstanding Bearish Profitability Narrative

Alphatec Holdings (ATEC) closed out FY 2025 with Q4 revenue of US$212.9 million and a basic EPS loss of US$0.14, alongside net income excluding extra items of a US$21.7 million loss, setting a clear snapshot of where the business stands on growth and profitability. The company has seen quarterly revenue move from US$150.7 million in Q3 2024 to US$196.5 million in Q3 2025, and then to US$212.9 million in Q4 2025. Basic EPS losses shifted from US$0.28 in Q3 2024 to US$0.19 in Q3 2025 and...
NasdaqGM:IRMD
NasdaqGM:IRMDMedical Equipment

Is It Too Late To Reassess IRADIMED (IRMD) After Its Strong Multi‑Year Share Price Run?

If you are wondering whether IRADIMED's current share price offers good value or is already pricing in a lot of optimism, you are in the right place. The stock last closed at US$100.50, with returns of 0.4% over 30 days, 5.2% year to date, 83.1% over 1 year, 170.0% over 3 years and 371.2% over 5 years. These figures may have changed how investors think about both its potential and its risks. Recent news coverage has focused on IRADIMED's position in medical technology and its role in...
NasdaqGS:DUOL
NasdaqGS:DUOLConsumer Services

Is Duolingo (DUOL) Now Attractive After A 68.7% One Year Share Price Decline

If you are wondering whether Duolingo's current share price fairly reflects its potential, you are not alone. This article is aimed at helping you weigh what you are really paying for the business. Over the last week the stock returned 5.7%, but that sits against a 19.6% decline over 30 days, a 33.4% decline year to date, and a 68.7% decline over the past year, with a 3 year return of a 2.0% decline. These moves have arrived alongside ongoing interest in language learning platforms and wider...
NYSE:PFE
NYSE:PFEPharmaceuticals

Pfizer Targets Obesity And Oncology To Rebuild Post COVID 19 Growth

Pfizer secured exclusive commercialization rights to Sciwind's ecnoglutide in China for type 2 diabetes and potential obesity treatment. The company expanded its metabolic and obesity pipeline as it seeks a stronger position in this therapy area. The FDA granted full approval for BRAFTOVI in combination therapy for first line treatment of metastatic colorectal cancer with BRAF V600E mutation. BRAFTOVI is now the only targeted regimen of its kind approved for first line use in this specific...